Research programme: hepatitis C NS4 protein inhibitors - Eiger BiopharmaceuticalsAlternative Names: 4BAH2 inhibitors; NS4B-RNA inhibitors
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator Eiger BioPharmaceuticals
- Developer Eiger BioPharmaceuticals, Inc.
- Class Benzimidazoles; Indazoles; Small molecules
- Mechanism of Action Hepatitis C virus NS4 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 22 Mar 2016 Celladon has merged with Eiger BioPharmaceuticals and the combined company is now called Eiger BioPharmaceuticals, Inc.
- 04 Aug 2009 Eiger BioPharmaceuticals enters into a technology licensing agreement with Stanford University